- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
IPotential, the technology intellectual property (IP) experts, today announced Steve Knauer joined the company as chief patent counsel.
Knauer brings 15 years of experience in analyzing and prosecuting technology-related patents to the IPotential team, further enhancing IPotential's ability to evaluate and monetize patent assets. Knauer will be responsible for managing the analysis and evaluation of patents in support of IPotential's three business segments, Strategic Counseling, Patent Licensing and Patent Brokerage.
"Our ability to deliver the best possible price for our patent owners depends on our ability to identify and highlight the real value of their patents, and that begins and ends with a deep understanding of the scope and use of the patented invention. Steve's expertise, knowledge and extensive experience in evaluating patents and the technologies they cover will be a great complement to our management team and a benefit our customers," said Ron Epstein, CEO of IPotential. "Steve's decision to join IPotential further demonstrates our momentum, making it even stronger by attracting highly talented individuals, like Steve, who brings a substantial amount of patent and intellectual property experience to IPotential. I look forward to continuing the company's growth."
Previously IP Counsel for Gemplus, Knauer, managed all of the company's IP matters in the Americas including patent litigation, defending the company against patent assertions, analyzing the infringement of the company's patents, creating assertion-based patent licensing programs, and patent and trademark prosecution management. Knauer, prior to his tenure with Gemplus, was a partner at Flehr, Hohbach, Test, Albittron & Herbert where he prepared and prosecuted hundreds of patent applications on sophisticated technologies, including semiconductor devices, telecommunications systems, computer networks, software, nanotechnology and business methods. Additionally, he counseled clients on strategic IP matters, such as developing and managing their patent portfolios and providing validity and infringement analysis. Before Knauer began his legal career, he was a systems engineer at Rockwell International.
"IPotential's compelling business model, which is markedly different from typical patent licensing and brokerage firms, attracted me to the company," said Knauer. "By focusing on patents as a business asset, not just a strategic asset, IPotential excels at recognizing the true value of intellectual property and is therefore enabling greater monetization of patents for clients."
Knauer earned his Bachelor of Science degree in Electrical Engineering from the University of California, Los Angeles and his J.D. from the National Law Center at the George Washington University. He is a member of the California State Bar and is registered to practice before the U.S. Patent and Trademark Office.
IPotential is the technology industry’s leading strategic intellectual property (IP) service provider that specializes in assisting technology companies with complex intellectual property transactions and strategies including acquisition, sale, and licensing of intellectual property and the creation of business-relevant IP strategies.
For more information, please click here
Joe Chernesky, 650-572-8825
Shelton Group (for IPotential)
Katie Olivier, 972-239-5119 ext. 128 (Media)
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
UTHealth research looks at nanotechnology to help prevent preterm birth February 7th, 2016
Lithium battery catalyst found to harm key soil microorganism February 7th, 2016
Silicon-based metamaterials could bring photonic circuits February 1st, 2016
Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre: FDA Cleared Immuno-Oncology Technology to Resume Clinical Development for Solid Tumor Patients January 27th, 2016
Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016